This site is intended for healthcare professionals
Optimising anti-TNF treatment using biosimilars Learning Zone


Read time: 85 mins
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.

This Learning Zone has been developed to provide practical advice and considerations on the use of biosimilars covering such topics as timely initiation, dose optimisation, the role of therapeutic drug monitoring, and cycling vs switching for anti-TNFs. The importance of shared decision-making to improve adherence and persistence are also discussed, as well as how biosimilars are shaping anti-TNF exit strategies.

Expert Opinion

Know the latest insights on the use of αTNF biosimilars in rheumatoid arthritis? Watch these videos on treatment initation and optimisation.

Clinical Practice

Biological medicines have revolutionised healthcare since their development in the 1980’s. Recently, biosimilars have established their place in the clinic, benefitting almost every stakeholder in the healthcare system. So what are biosimilars and how could they be important to your practice?

Efficacy & Safety

The costs of anti-TNF products are often high, placing a financial burden on the healthcare system and at times limiting the access to these products. As an alternative, anti-TNF biosimilars enable earlier and wider access to appropriate therapy without the financial burden associated with the reference product. But does the efficacy and safety data for anti-TNF biosimilar treatments support their use in the treatment of key gastroenterology, rheumatology, and dermatology conditions?

Practical Advice

Biosimilars offer health care practices large potential cost savings and the opportunity to widen patient access to treatment, but what are the different factors that are important to consider when prescribing biosimilars in gastroenterology, rheumatology and dermatology?

Decision Making

Shared decision making (SDM) between physicians and patients, as opposed to HCPs making decisions on behalf of patients without proper information and consent, is supported by a growing base of evidence across a range of therapy areas from rheumatologic disease to cancer. So, how can SDM boost treatment adherence and persistence for biologics and/or biosimilars?